| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.12.25 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 19.12.2025 | 775 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 19.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 19.12.2025ISIN NameCA74349R1055 PROPHECY... ► Artikel lesen | |
| 11.12.25 | NGM MARKET NOTICE: #25-119 Decision on delisting of Diagonal Bio AB from Nordic SME | 5 | Cision News | ||
| 11.12.25 | XFRA 9F1: AUSSETZUNG/SUSPENSION | 300 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILDIAGONAL BIO AB... ► Artikel lesen | |
| DIAGONAL BIO Aktie jetzt für 0€ handeln | |||||
| 11.12.25 | NGM MARKET NOTICE: #25-118 Trading halt in Diagonal Bio AB | 6 | Cision News |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 11,390 | -1,30 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM | CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,190 | +1,17 % | PacBio Announces the Appointment of Chris Gibson to the Board of Directors | MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher... ► Artikel lesen | |
| ATAIBECKLEY | 3,220 | +4,55 % | Psychedelika-Forschung gewinnt an Dynamik: Emyria Limited und AtaiBeckley im Fokus neuer PTBS-Therapien | ||
| BIOMERIEUX | 90,25 | +0,06 % | BioMerieux SA Profit Declines In Full Year | PARIS (dpa-AFX) - BioMerieux SA (EYWN.MU) reported earnings for full year that Drops, from the same period last yearThe company's bottom line totaled EUR397.5 million, or EUR3.34 per share.... ► Artikel lesen | |
| BIO GREEN MED SOLUTION | 1,040 | +1,96 % | Bio Green Med Solution, Inc.: Bio Green Med Solution Reports Third Quarter Financial Results and Provides Business Update | KUALA LUMPUR, Malaysia, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS, NASDAQ: BGMSP; "BGMS" or the "Company" (formerly Cyclacel Pharmaceuticals, Inc.)), a diversified... ► Artikel lesen | |
| ANAPTYSBIO | 56,50 | 0,00 % | AnaptysBio, Inc.: Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update | Anaptys to spin-off biopharma operations into First Tracks Biotherapeutics, with a target distribution date of April 20, 2026Anaptys to manage the financial collaborations for Jemperli with GSK and... ► Artikel lesen | |
| GENUS | 29,000 | 0,00 % | Dividendenbekanntmachungen (05.03.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AMERICAN ASSETS TRUST INC US0240131047 0,34 USD 0,2922 EUR ARMSTRONG WORLD INDUSTRIES INC US04247X1028 0,339 USD 0,2914 EUR ASSOCIATED... ► Artikel lesen | |
| ABIONYX PHARMA | 3,270 | +7,92 % | ABIONYX Pharma Achieves Major Milestone in apoA-I Biomanufacturing with Breakthrough in Synthetic Sphingomyelin Production | Regulatory News:
ABIONYX Pharma, (FR0012616852 ABNX eligible for PEA PME), a next-generation biopharmaceutical company developing innovative therapies in sepsis and critical care based on an... ► Artikel lesen | |
| MEIRAGTX | 6,550 | 0,00 % | Piper Sandler cuts MeiraGTx stock price target on valuation | ||
| XTL BIOPHARMACEUTICALS | 2,079 | +0,34 % | XFRA ISIN CHANGE | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenUS68237Q2030 Onconetix Inc. 24.03.2026 US68237Q3020 Onconetix Inc. 25.03.2026 Tausch 5:1US98386D3070 XTL Biopharmaceuticals... ► Artikel lesen | |
| AKESO | 13,600 | +0,74 % | Akeso, Inc.: Akeso Reports Full-Year 2025 Financial Results | HONG KONG, March 26, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced its 2025 annual results, highlighting a year of comprehensive... ► Artikel lesen | |
| MAAT PHARMA | 6,380 | -0,93 % | MaaT Pharma Presents the ARES Phase 3 Pivotal Trial Final Data During the Presidential Plenary Session at the 52nd Annual Meeting of the European Society for Bone and Marrow Transplantation | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| ISOFOL MEDICAL | 0,045 | -2,18 % | Isofol Medical AB: Isofol secures license rights for arfolitixorin in autism | GOTHENBURG, Sweden, March 18, 2026 - Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announces that the company has expanded its global exclusive license agreement for arfolitixorin to also... ► Artikel lesen | |
| QIAGEN | 33,900 | -3,32 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| ARTELO BIOSCIENCES | 12,790 | +300,94 % | Morning Market Movers: Artelo Biosciences, Onconetix, Datacentrex, Robin Energy See Big Swings | OTTAWA (dpa-AFX) - At 8:30 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen |